Cancer, a disease that is yet to be cured, is known for its high mortality rates and higher infected patient population. According to the predictions made by the American Cancer Society, 1,688,780 are estimated to be diagnosed with cancer and 600,920 are estimated to die of cancer in 2017 (A., 2017). Although several antitumor drugs have been created to treat the disease, the side effects a patient would obtain are also severe and unwanted. Chemotherapy has immediate side effects, including nausea and vomiting, early side effects, including bone marrow toxicity, delayed, including hair loss, and late side effects, which include bone and joint problems (Emeritus Prof., 2017). Other drugs used to treat cancer include Avastin, Fluorouracil (5-FU), Vinblastine, and Methotrexate (Nimmi, 2008-2017).
O-(4-methyl)-phenyl-N-(9'-acridinyl)-hydroxylamine, an antitumor drug, is a derivative of O-phenyl-N-(9’-acridinyl)-hydroxylamine. 9-aminoacridine compounds plant themselves between DNA base pairs, which is also known as DNA intercalation. This then causes the cell to undergo programmed cell death, also known as apoptosis. The synthetization of 9-aminoacridine derivatives has been proven to be successful as a catalytic inhibitor. Although O-(4-methyl)-phenyl-N-(9'-acridinyl)-hydroxylamine is yet to be created, the expected results are estimated to be better to 9-aminoacridine compounds.
Unlike 9-aminoacridine compounds, O-(4-methyl)-phenyl-N-(9'-acridinyl)-hydroxylamine would intercalate and hold stronger bonds between DNA base pairs, caused by topoisomerase compounds (Hoshino, Sato, Akahane, Yoshida, Hayakawa, Sato, Une, Osada, 1991). This would allow for a smaller dosage to be inputted into the patient, thus causing less side effects. This drug is different from O-phenyl-N-(9’-acridinyl)-hydroxylamine due to the attached methyl group. The methyl group acts as an electron donating group causing the base pairs to be bonded less strong together when compared to O-phenyl-N-(9’-acridinyl)-hydroxylamine, which should cause the drug to affect less normal cells and more cancer cells (Tewey, Chen, Nelson, Liu, 1984). This sparks the question of whether O-(4-methyl)-phenyl-N-(9'-acridinyl)-hydroxylamine can successfully be synthesized in high yields and whether or not it will have the desired effect on cancer cells.
O-(4-methyl)-phenyl-N-(9'-acridinyl)-hydroxylamine, an antitumor drug, is a derivative of O-phenyl-N-(9’-acridinyl)-hydroxylamine. 9-aminoacridine compounds plant themselves between DNA base pairs, which is also known as DNA intercalation. This then causes the cell to undergo programmed cell death, also known as apoptosis. The synthetization of 9-aminoacridine derivatives has been proven to be successful as a catalytic inhibitor. Although O-(4-methyl)-phenyl-N-(9'-acridinyl)-hydroxylamine is yet to be created, the expected results are estimated to be better to 9-aminoacridine compounds.
Unlike 9-aminoacridine compounds, O-(4-methyl)-phenyl-N-(9'-acridinyl)-hydroxylamine would intercalate and hold stronger bonds between DNA base pairs, caused by topoisomerase compounds (Hoshino, Sato, Akahane, Yoshida, Hayakawa, Sato, Une, Osada, 1991). This would allow for a smaller dosage to be inputted into the patient, thus causing less side effects. This drug is different from O-phenyl-N-(9’-acridinyl)-hydroxylamine due to the attached methyl group. The methyl group acts as an electron donating group causing the base pairs to be bonded less strong together when compared to O-phenyl-N-(9’-acridinyl)-hydroxylamine, which should cause the drug to affect less normal cells and more cancer cells (Tewey, Chen, Nelson, Liu, 1984). This sparks the question of whether O-(4-methyl)-phenyl-N-(9'-acridinyl)-hydroxylamine can successfully be synthesized in high yields and whether or not it will have the desired effect on cancer cells.